These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 17977977)

  • 1. Herpes simplex virus type 1 preferentially targets human colon carcinoma: role of extracellular matrix.
    Kolodkin-Gal D; Zamir G; Edden Y; Pikarsky E; Pikarsky A; Haim H; Haviv YS; Panet A
    J Virol; 2008 Jan; 82(2):999-1010. PubMed ID: 17977977
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Positron emission tomography of herpes simplex virus 1 oncolysis.
    Kuruppu D; Brownell AL; Zhu A; Yu M; Wang X; Kulu Y; Fuchs BC; Kawasaki H; Tanabe KK
    Cancer Res; 2007 Apr; 67(7):3295-300. PubMed ID: 17409438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Herpes simplex virus delivery to orthotopic rectal carcinoma results in an efficient and selective antitumor effect.
    Kolodkin-Gal D; Edden Y; Hartshtark Z; Ilan L; Khalaileh A; Pikarsky AJ; Pikarsky E; Rabkin SD; Panet A; Zamir G
    Gene Ther; 2009 Jul; 16(7):905-15. PubMed ID: 19440231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prodrug bioactivation and oncolysis of diffuse liver metastases by a herpes simplex virus 1 mutant that expresses the CYP2B1 transgene.
    Pawlik TM; Nakamura H; Mullen JT; Kasuya H; Yoon SS; Chandrasekhar S; Chiocca EA; Tanabe KK
    Cancer; 2002 Sep; 95(5):1171-81. PubMed ID: 12209705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncolysis by viral replication and inhibition of angiogenesis by a replication-conditional herpes simplex virus that expresses mouse endostatin.
    Mullen JT; Donahue JM; Chandrasekhar S; Yoon SS; Liu W; Ellis LM; Nakamura H; Kasuya H; Pawlik TM; Tanabe KK
    Cancer; 2004 Aug; 101(4):869-77. PubMed ID: 15305421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An oncolytic herpes simplex virus type 1 selectively destroys diffuse liver metastases from colon carcinoma.
    Yoon SS; Nakamura H; Carroll NM; Bode BP; Chiocca EA; Tanabe KK
    FASEB J; 2000 Feb; 14(2):301-11. PubMed ID: 10657986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concurrent chemotherapy inhibits herpes simplex virus-1 replication and oncolysis.
    Kulu Y; Kawasaki H; Donahue JM; Kasuya H; Cusack JC; Choi EW; Kuruppu DK; Fuchs BC; Tanabe KK
    Cancer Gene Ther; 2013 Feb; 20(2):133-40. PubMed ID: 23348635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Positron emission tomography-based imaging of transgene expression mediated by replication-conditional, oncolytic herpes simplex virus type 1 mutant vectors in vivo.
    Jacobs A; Tjuvajev JG; Dubrovin M; Akhurst T; Balatoni J; Beattie B; Joshi R; Finn R; Larson SM; Herrlinger U; Pechan PA; Chiocca EA; Breakefield XO; Blasberg RG
    Cancer Res; 2001 Apr; 61(7):2983-95. PubMed ID: 11306477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multi-attenuated herpes simplex virus-1 mutant G207 exerts cytotoxicity against epithelial ovarian cancer but not normal mesothelium and is suitable for intraperitoneal oncolytic therapy.
    Coukos G; Makrigiannakis A; Montas S; Kaiser LR; Toyozumi T; Benjamin I; Albelda SM; Rubin SC; Molnar-Kimber KL
    Cancer Gene Ther; 2000 Feb; 7(2):275-83. PubMed ID: 10770637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Susceptibility of Human and Murine Dermal Fibroblasts to Herpes Simplex Virus 1 in the Absence and Presence of Extracellular Matrix.
    Wirtz L; De La Cruz NC; Möckel M; Knebel-Mörsdorf D
    J Virol; 2022 Feb; 96(4):e0206821. PubMed ID: 34908440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angiogenic response caused by oncolytic herpes simplex virus-induced reduced thrombospondin expression can be prevented by specific viral mutations or by administering a thrombospondin-derived peptide.
    Aghi M; Rabkin SD; Martuza RL
    Cancer Res; 2007 Jan; 67(2):440-4. PubMed ID: 17234749
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNA regulation of oncolytic herpes simplex virus-1 for selective killing of prostate cancer cells.
    Lee CY; Rennie PS; Jia WW
    Clin Cancer Res; 2009 Aug; 15(16):5126-35. PubMed ID: 19671871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of tumor invasiveness, the extracellular matrix, and chromatin sequestration in the susceptibility of uveal melanoma to herpes simplex virus type 1.
    Valyi-Nagy K; Folberg R; Valyi-Nagy T; Maniotis AJ
    Exp Eye Res; 2007 May; 84(5):991-1000. PubMed ID: 17386925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Herpes simplex virus 1 (HSV-1) for cancer treatment.
    Shen Y; Nemunaitis J
    Cancer Gene Ther; 2006 Nov; 13(11):975-92. PubMed ID: 16604059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Restrictions that control herpes simplex virus type 1 infection in mouse brain ex vivo.
    Cohen M; Braun E; Tsalenchuck Y; Panet A; Steiner I
    J Gen Virol; 2011 Oct; 92(Pt 10):2383-2393. PubMed ID: 21697348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel system to study adenovirus tropism to normal and malignant colon tissues.
    Kolodkin-Gal D; Zamir G; Pikarski E; Pikarski A; Shimony N; Wu H; Haviv YS; Panet A
    Virology; 2007 Jan; 357(1):91-101. PubMed ID: 16962151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Herpes Simplex Virus 1 Infection Promotes the Growth of a Subpopulation of Tumor Cells in Three-Dimensional Uveal Melanoma Cultures.
    Valyi-Nagy T; Fredericks B; Ravindra A; Hopkins J; Shukla D; Valyi-Nagy K
    J Virol; 2018 Oct; 92(19):. PubMed ID: 30045986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumour-specific triple-regulated oncolytic herpes virus to target glioma.
    Delwar ZM; Liu G; Kuo Y; Lee C; Bu L; Rennie PS; Jia WW
    Oncotarget; 2016 May; 7(19):28658-69. PubMed ID: 27070093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor genotype determines susceptibility to oncolytic herpes simplex virus mutants: strategies for clinical application.
    Smith KD; Shao MY; Posner MC; Weichselbaum RR
    Future Oncol; 2007 Oct; 3(5):545-56. PubMed ID: 17927520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Active immunotherapy: oncolytic virus therapy using HSV-1.
    Todo T
    Adv Exp Med Biol; 2012; 746():178-86. PubMed ID: 22639168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.